At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 70 enrolled
Drug / intervention
BIBW 2992 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
In Brief
A Phase 1 clinical trial evaluating BIBW 2992 and BIBF 1120 for Neoplasms. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The primary objective of this trial is to determine the Maximum Tolerated Dose (MTD) of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly. The MTD will provide dosing recommendation for subsequent phase II trials in patients with metastatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesFrance
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedOct 2009
Primary CompletionDec 2012
Study CompletionJul 2014
TodayJul 2026
First PostedOct 20, 2009
Enrollment StartOct 1, 2009
Primary CompletionDec 1, 2012
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 16.7 years ago
Interventions
BIBW 2992drug
EGFR inhibitor
BIBF 1120drug
VEGF inhibitor